Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies.

Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases.

The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2.

Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation.

Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.